

Madhav Dhodapkar

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6343114/publications.pdf>

Version: 2024-02-01

33
papers

1,243
citations

623734

14
h-index

610901

24
g-index

33
all docs

33
docs citations

33
times ranked

1954
citing authors

#	ARTICLE	IF	CITATIONS
1	Plasma cells expression from smouldering myeloma to myeloma reveals the importance of the PRC2 complex, cell cycle progression, and the divergent evolutionary pathways within the different molecular subgroups. <i>Leukemia</i> , 2022, 36, 591-595.	7.2	6
2	Benefits of Autologous Stem Cell Transplantation for Elderly Myeloma Patients in the Last Quarter of Life. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 75.e1-75.e7.	1.2	5
3	Determinants of Neutralizing Antibody Response After SARS CoV-2 Vaccination in Patients With Myeloma. <i>Journal of Clinical Oncology</i> , 2022, 40, 3057-3064.	1.6	31
4	Humoral Responses Against SARS-CoV-2 and Variants of Concern After mRNA Vaccines in Patients With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia. <i>Journal of Clinical Oncology</i> , 2022, 40, 3020-3031.	1.6	26
5	Mission, Organization, and Future Direction of the Serological Sciences Network for COVID-19 (SeroNet) Epidemiologic Cohort Studies. <i>Open Forum Infectious Diseases</i> , 2022, 9, .	0.9	5
6	Antibody Response to COVID-19 mRNA Vaccine in Patients With Lung Cancer After Primary Immunization and Booster: Reactivity to the SARS-CoV-2 WT Virus and Omicron Variant. <i>Journal of Clinical Oncology</i> , 2022, 40, 3808-3816.	1.6	19
7	Role of MBD3-SOX2 axis in residual myeloma following pomalidomide. <i>Leukemia</i> , 2021, 35, 3319-3323.	7.2	4
8	Co-evolution of Immune Response in Multiple Myeloma: Implications for Immune Prevention. <i>Frontiers in Immunology</i> , 2021, 12, 632564.	4.8	8
9	Tandem high-dose influenza vaccination is associated with more durable serologic immunity in patients with plasma cell dyscrasias. <i>Blood Advances</i> , 2021, 5, 1535-1539.	5.2	17
10	How to Provide the Needed Protection from COVID-19 to Patients with Hematologic Malignancies. <i>Blood Cancer Discovery</i> , 2021, 2, 562-567.	5.0	22
11	Viral Immunity and Vaccines in Hematologic Malignancies: Implications for COVID-19. <i>Blood Cancer Discovery</i> , 2021, 2, 9-12.	5.0	20
12	Daratumumab with Pomalidomide and Dexamethasone at First Relapse in Relapsed and/or Refractory Multiple Myeloma (RRMM) Patients. <i>Blood</i> , 2021, 138, 1616-1616.	1.4	0
13	BRAF Mutations and Inflammatory Gene Expression in Myeloma Cells from Patients with Renal Dysfunction. <i>Blood</i> , 2021, 138, 1624-1624.	1.4	0
14	Single-Cell RNA-Seq Analysis of CD138-Depleted Bone Marrow Samples Reveals Genetic Alterations and Disease Progression Correlate with Tumor and Bone Marrow Immune Microenvironment in the Mmrf Compass Study. <i>Blood</i> , 2021, 138, 2691-2691.	1.4	0
15	The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma. , 2020, 8, e000734.		27
16	Race-Dependent Differences in Risk, Genomics, and Epstein-Barr Virus Exposure in Monoclonal Gammopathies: Results of SWOG S0120. <i>Clinical Cancer Research</i> , 2020, 26, 5814-5819.	7.0	4
17	Downregulation of PA28 \pm induces proteasome remodeling and results in resistance to proteasome inhibitors in multiple myeloma. <i>Blood Cancer Journal</i> , 2020, 10, 125.	6.2	7
18	Long-Term Follow-Up Results of Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy and Risk-Adapted Maintenance Approach in Newly Diagnosed Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2020, 38, 1928-1937.	1.6	148

#	ARTICLE	IF	CITATIONS
19	REGN5458, a BCMA x CD3 Bispecific Monoclonal Antibody, Induces Deep and Durable Responses in Patients with Relapsed/Refractory Multiple Myeloma (RRMM). <i>Blood</i> , 2020, 136, 41-42.	1.4	48
20	Integrated Cytof, Scrna-Seq and Cite-Seq Analysis of Bone Marrow Immune Microenvironment in the Mmrf Compass Study. <i>Blood</i> , 2020, 136, 28-29.	1.4	2
21	Advanced Imaging and Targeted Myeloma Lesion Biopsies to Enhance Global Response Assessment and Evaluate Spatial Heterogeneity in Multiple Myeloma. <i>Blood</i> , 2020, 136, 20-22.	1.4	0
22	Architecture of Sample Preparation and Data Governance of Immuno-Genomic Data Collected from Bone Marrow and Peripheral Blood Samples Obtained from Multiple Myeloma Patients. <i>Blood</i> , 2020, 136, 17-18.	1.4	1
23	Evaluating Outcomes for Autologous Hematopoietic Cell Transplantation for Diffuse Large B-Cell Lymphoma in the CAR-T Era. <i>Blood</i> , 2020, 136, 20-21.	1.4	0
24	Role of clonoSEQ [®] , a Next-Generation Sequencing (NGS) Assay and PET/CT As a Measure of Minimal Residual Disease Negativity Among Patients with Multiple Myeloma. <i>Blood</i> , 2020, 136, 50-51.	1.4	0
25	Identification and Validation of CD138- Multiple Myeloma Immune and Tumor Subpopulations Using Cross Center Scrna-Seq Data. <i>Blood</i> , 2020, 136, 15-15.	1.4	0
26	Characterization of Plasma and Immune Cells Molecular Landscape That Play a Role in Rapid Progression of Multiple Myeloma Using Cross Center Scrna-Seq Study. <i>Blood</i> , 2020, 136, 6-8.	1.4	0
27	Multiple myeloma immunoglobulin lambda translocations portend poor prognosis. <i>Nature Communications</i> , 2019, 10, 1911.	12.8	109
28	Early alterations in stem-like/marrow-resident T cells and innate and myeloid cells in preneoplastic gammopathy. <i>JCI Insight</i> , 2019, 4, .	5.0	107
29	Microenvironment-dependent growth of preneoplastic and malignant plasma cells in humanized mice. <i>Nature Medicine</i> , 2016, 22, 1351-1357.	30.7	132
30	Four genes predict high risk of progression from smoldering to symptomatic multiple myeloma (SWOG S0120). <i>Haematologica</i> , 2015, 100, 1214-1221.	3.5	44
31	Clinical and pharmacodynamic analysis of pomalidomide dosing strategies in myeloma: impact of immune activation and cereblon targets. <i>Blood</i> , 2015, 125, 4042-4051.	1.4	103
32	Clinical, genomic, and imaging predictors of myeloma progression from asymptomatic monoclonal gammopathies (SWOG S0120). <i>Blood</i> , 2014, 123, 78-85.	1.4	173
33	Frequent and specific immunity to the embryonal stem cell-associated antigen SOX2 in patients with monoclonal gammopathy. <i>Journal of Experimental Medicine</i> , 2007, 204, 831-840.	8.5	175